G1 Therapeutics, Inc.

GTHX

US3621LQ1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
2.28 ^USD	+1.33%		-8.06%	-25.25%

06-25	Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating	MT
06-25	HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating	MT

G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024

June 24, 2024 at 06:30 am

G1 Therapeutics, Inc. reaffirmed earnings guidance for the full year 2024. The company expects to generate between $60 million and $70 million in COSELA net revenue in 2024.

Latest news about G1 Therapeutics, Inc.

Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating	06-25	MT
HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating	06-25	MT
Top Midday Decliners	06-24	MT
Wedbush Adjusts Price Target on G1 Therapeutics to $3 From $5, Maintains Outperform Rating	06-24	MT
Sector Update: Health Care Stocks Advance Premarket Monday	06-24	MT
US Equity Futures Mixed in Premarket Action as Traders Eye Friday's Inflation Data	06-24	MT
Transcript : G1 Therapeutics, Inc. - Special Call	06-24
Top Premarket Decliners	06-24	MT
G1 Therapeutics Halts Phase 3 Breast Cancer Drug Trial As Data Disappoints	06-24	MT
G1 Therapeutics' breast cancer drug fails in late-stage trial	06-24	RE
G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer	06-24	CI
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024	06-24	CI
TScan Therapeutics, Inc Announces Board and Committee Changes	06-14	CI
G1 Therapeutics, Inc. Announces the Presentation of Mature Phase 2 Clinical Trial Results	05-28	CI
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting	05-23	CI
Sector Update: Health Care Stocks Lower Premarket Wednesday	05-22	MT
G1 Therapeutics Grants Deimos Biosciences License to Market Anti-Radiation Treatment -- Shares Up Pre-Bell	05-22	MT
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses	05-22	CI
Transcript : G1 Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M	05-01	MT
G1 Therapeutics, Inc. Reaffirms Earnings Guidance for the Full Year 2024	05-01	CI
G1 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib	05-01	CI
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	02-28	MT

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for G1 Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.28 USD

Average target price

4.5 USD

Spread / Average Target

+97.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
G1 THERAPEUTICS, INC.	-25.25%	119M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs